Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HS-20137 in adults with moderate-to-severe plaque psoriasis
CTR20250602Phase 3Active
- Sponsor
- Qiansin
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing HS-20137 with Placebo (2 arms). Primary endpoints: PASI 90 response rate at Week 16 and sPGA 0/1 response rate at Week 16. Started Mar 2025; status: active.
02
Drugs
QX004N
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20250602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250602.